Gastrointestinal Cancer | Specialty

Biological Breakthroughs in Pancreas Cancer

October 10th 2017

Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer

October 6th 2017

Harry H. Yoon, MD discussed the promise of immunotherapy and emphasized the importance of mismatch repair deficiency testing in gastric/GEJ Cancer.

Pancreatic Cancer Advocacy Group Leads the Charge for Innovation

October 5th 2017

In its fight against pancreatic cancer, the Pancreatic Cancer Action Network aims to improve current survival and double survival by 2020.

Dr. Welling on the Efficacy of Nivolumab in HCC

October 4th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Novel Targets and Biomarkers Emerge in Pancreatic Cancer

October 2nd 2017

There is an urgent need for new approaches, particularly since pancreatic cancer is expected to become the second leading cause of cancer-related mortality by 2030.

PEGPH20 Offers New Mechanism for Attacking Pancreas Tumors

September 29th 2017

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

Expert Discusses Ongoing Advances With Immunotherapy in CRC

September 28th 2017

Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer.

PEGPH20 Could Alter Frontline Treatment in Pancreatic Cancer

September 27th 2017

Optimizing frontline therapy for patients with pancreatic cancer is an ongoing focal point in the field.

FDA Accepts Lenvatinib Application for Advanced HCC

September 27th 2017

The FDA has accepted a supplemental new drug application for lenvatinib as a frontline systemic treatment for patients with advanced hepatocellular carcinoma.

Dr. Alberts Discusses Updates in Liver Cancer

September 26th 2017

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Grothey Highlights Biomarker Research in CRC

September 26th 2017

Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.

Therapies in Development to Improve Outcomes in BRAF-Mutated CRC

September 26th 2017

Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC

Therapeutic Advancements Changing Liver Cancer Paradigm

September 26th 2017

Steven R. Alberts, MD, discusses current advancements being made for patients with advanced liver cancer.

Dr. Larson on Immunotherapy for Colorectal Cancer

September 26th 2017

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Dr. Yoon on Immunotherapy in Gastric Cancer

September 25th 2017

Harry H. Yoon, MD, associate professor of oncology, Mayo Clinic, discusses the benefits demonstrated with nivolumab (Opdivo) and pembrolizumab (Keytruda) for patients with gastric cancer.

FDA Approves Nivolumab for Hepatocellular Carcinoma

September 23rd 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib.

Dr. Saab on Immunotherapy in MSI-H GI Malignancies

September 23rd 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses immunotherapy in a patient with microsatellite instability-high (MSI-H) gastrointestinal malignancies.

FDA Approves Pembrolizumab for PD-L1+ Gastric Cancer

September 22nd 2017

The FDA has approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.

Expert Reflects on Recent Trial Results in CRC and Small Bowel Cancer

September 21st 2017

Heinz-Josef Lenz, MD, discusses his study of molecular variations between small bowel adenocarcinomas, right-sided colon cancers, and gastroesophageal cancers.

Dr. Janjigian Discusses MSI Testing in Gastric Cancer

September 19th 2017

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.